Business
PAOG Sees Broader Cannabis Pharma Treatment Opportunity
PAOG Sees Broader Cannabis Pharma Treatment Opportunity.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Sees Broader Cannabis Pharma Treatment Opportunity\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Sees Broader Cannabis Pharma Treatment Opportunity\nPR Newswire\nSANDUSKY, Ohio, Sept. 24, 2020\n\n\n\nSANDUSKY, Ohio, Sept. 24, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).\nOn July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).  RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\" \nIn an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. \nWith RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.\nThe expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research.  Two studies in particular, both of which highlight the research behind GW Pharmaceuticals' cannabinoid treatments, shed light on PAOG's wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.\nOne of the two studies is focused on CBD and the other on THC.  The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells.  The THC report seems to validate its ability to rel...